Global News | World latest News| Trending News
Researchers hope targeting CDK2 can overcome resistance to CDK4/6 inhibitors Implications for treatment of breast, pancreatic, other cancers Findings published in Nature Communications BUFFALO, N.Y. — An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic resistance to common breast cancer drugs — including a class…
Invited talk highlights link between patients’ physical function, CAR T outcomes Holtan to be honored for contributions to combating graft-vs.-host disease Other studies: Prospect for CAR T in breast cancer, ways to improve outcomes BUFFALO, N.Y. — Discoveries made by experts from Roswell Park Comprehensive Cancer Center will be featured at an international conference focusing…
Specific changes in the cervicovaginal microbiome set the stage for chlamydia Findings in women of color, disproportionately affected by infections but understudied Team reveals previously unknown subtype of BV, bacterial vaginosis January 15, 2025—(BRONX, NY and BUFFALO, NY)—Women who develop bacterial vaginosis (BV) often later acquire chlamydia, a common and potentially serious sexually transmitted bacterial…
One of the deadliest types of breast cancer, TNBC has a high recurrence rate Study shows IMPDH2 inhibitors reduce growth of chemo-resistant tumors Findings published in Nature’s Scientific Reports BUFFALO, N.Y. — Triple-negative breast cancer, or TNBC, presents numerous treatment challenges. Compared with other forms of breast cancer, it’s more likely to have spread…
Western New York magazine publishes new list of the region’s Top Doctors List compiled through peer surveys of WNY physicians Roswell Park physicians recognized in 35 categories – highest ever BUFFALO, N.Y. — As the year comes to a close, Roswell Park Comprehensive Cancer Center honors the 143 physicians across 35 specialties named to Buffalo…
Findings from new preclinical study reported in Oncogene Work helps explain why advanced prostate tumors may resist current treatments HSP60 inhibition emerges as promising treatment strategy BUFFALO, N.Y. — A team of researchers at Roswell Park Comprehensive Cancer Center, led by Dhyan Chandra, PhD, has discovered a new therapeutic target for neuroendocrine prostate cancer, a rare…
New York’s first cell and gene therapy hub Expected to attract leading life science companies, new jobs Roswell Park’s cell therapy team includes pioneers in the field NOTE: This press release was originally issued by New York State Governor Kathy Hochul and is reproduced here with permission. See a multimedia newsroom with a fact sheet…
Newswise — BUFFALO, N.Y. — Researchers from Roswell Park Comprehensive Cancer Center will present compelling findings showcasing significant benefits of resistance training for patients with multiple myeloma, in a talk at the 66th American Society of Hematology (ASH) Annual Meeting. The study, led by Jens Hillengass, MD, PhD, and Janine Joseph, MS, MBA, presents new…
Newswise — BUFFALO, N.Y. — The results of two important lymphoma studies led by experts at Roswell Park Comprehensive Cancer Center will be presented during oral abstract sessions this morning at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California. Lymphoma is a type of blood cancer that causes…
Newswise — BUFFALO, N.Y. — Research out of Roswell Park Comprehensive Cancer Center has shed light on how the drug venetoclax (brand name Venclexta) works synergistically with CAR T-cell immunotherapy to combat chronic lymphocytic leukemia (CLL), the most common type of leukemia in the U.S. Matthew Cortese, MD, MPH, Assistant Professor of Oncology in Roswell Park’s departments of Medicine…
